Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 21;15(3):804.
doi: 10.3390/ma15030804.

Applications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders

Affiliations
Review

Applications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders

Tanima Bhattacharya et al. Materials (Basel). .

Abstract

The strategies involved in the development of therapeutics for neurodegenerative disorders are very complex and challenging due to the existence of the blood-brain barrier (BBB), a closely spaced network of blood vessels and endothelial cells that functions to prevent the entry of unwanted substances in the brain. The emergence and advancement of nanotechnology shows favourable prospects to overcome this phenomenon. Engineered nanoparticles conjugated with drug moieties and imaging agents that have dimensions between 1 and 100 nm could potentially be used to ensure enhanced efficacy, cellular uptake, specific transport, and delivery of specific molecules to the brain, owing to their modified physico-chemical features. The conjugates of nanoparticles and medicinal plants, or their components known as nano phytomedicine, have been gaining significance lately in the development of novel neuro-therapeutics owing to their natural abundance, promising targeted delivery to the brain, and lesser potential to show adverse effects. In the present review, the promising application, and recent trends of combined nanotechnology and phytomedicine for the treatment of neurological disorders (ND) as compared to conventional therapies, have been addressed. Nanotechnology-based efforts performed in bioinformatics for early diagnosis as well as futuristic precision medicine in ND have also been discussed in the context of computational approach.

Keywords: bioinformatics; nanomedicine; nanoparticles; neurodegenerative diseases; phytomedicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Neurodegenerative diseases and the types of neurons affected.
Figure 2
Figure 2
A schematic presentation of nano-informatic (nanotechnology and bioinformatics) in present dementia or neuro-disorder research.

References

    1. Bensadoun J.-C., Almeida L.P.d., Fine E.G., Tseng J.L., Déglon N., Aebischer P. Comparative study of GDNF delivery systems for the CNS: Polymer rods, encapsulated cells, and lentiviral vectors. J. Control. Release. 2003;87:107–115. doi: 10.1016/S0168-3659(02)00353-X. - DOI - PubMed
    1. Kishima H., Poyot T., Bloch J., Dauguet J., Conde F., Dolle F., Hinnen F., Pralong W., Palfi S., Deglon N., et al. Encapsulated GDNF-producing C2C12 cells for Parkinson’s disease: A pre-clinical study in chronic MPTP-treated baboons. Neurobiol. Dis. 2004;16:428–439. doi: 10.1016/j.nbd.2004.03.012. - DOI - PubMed
    1. McArthur J.C. HIV dementia: An evolving disease. J. Neuroimmunol. 2004;157:3–10. doi: 10.1016/j.jneuroim.2004.08.042. - DOI - PubMed
    1. Menei P., Montero-Menei C., Venier M.C., Benoit J.P. Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert Opin. Drug Deliv. 2005;2:363–376. doi: 10.1517/17425247.2.2.363. - DOI - PubMed
    1. Flachenecker P. Epidemiology of neuroimmunological diseases. J. Neurol. 2006;253((Suppl. 5)):V2–V8. doi: 10.1007/s00415-006-5001-3. - DOI - PubMed

LinkOut - more resources